Atlas Trials

Astellas Pharma China, Inc.

24 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Astellas Pharma China, Inc.

RecordFirmDate
A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients (NCT05152628)Astellas Pharma China, Inc.2022-01-11
A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients (NCT05153915)Astellas Pharma China, Inc.2021-12-30
A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy (NCT04995419)Astellas Pharma China, Inc.2021-07-22
A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects (NCT04793204)Astellas Pharma China, Inc.2021-03-24
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder (NCT04562090)Astellas Pharma China, Inc.2021-01-06
A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants (NCT04501640)Astellas Pharma China, Inc.2020-09-21
A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause (NCT04451226)Astellas Pharma China, Inc.2020-07-30
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause (NCT04234204)Astellas Pharma China, Inc.2020-03-17
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects (NCT04143477)Astellas Pharma China, Inc.2019-12-05
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma (NCT04086758)Astellas Pharma China, Inc.2019-10-18
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients (NCT03644485)Astellas Pharma China, Inc.2018-10-21
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) (NCT03660059)Astellas Pharma China, Inc.2018-09-27

Track Astellas Pharma China, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.